Atrium Therapeutics (RNA) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tiziana Life Sciences is the larger company by market cap ($141.9 million vs $136.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNA | TLSA |
|---|---|---|
| Share price | $7.97 | $1.12 |
| Market cap | $136.33M | $141.89M |
| 1-day change | +0.50% | +1.36% |
| YTD return | — | -26.17% |
| 1-year return | — | -49.31% |
| 5-year return | — | -27.15% |
| EPS (TTM) | $-5.44 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.77 | $2.30 |
| 52-week low | $7.63 | $0.76 |
| Distance from 52-week high | -52.47% | -51.52% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +213.68% | +615.70% |
| Average volume | 253.00K | 717.23K |
| Shares outstanding | 17.11M | 127.26M |
| Employees | — | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
RNA vs TLSA FAQ
Which is bigger, Atrium Therapeutics or Tiziana Life Sciences?
Tiziana Life Sciences (TLSA) is larger, with a market capitalization of $141.89M compared with $136.33M for Atrium Therapeutics (RNA).
Are Atrium Therapeutics and Tiziana Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.